1-10 of 10
Kevan M. Shokat
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization

Open Access
Lisa Werr, Dennis Plenker, Marcel A. Dammert, Carina Lorenz, Johannes Brägelmann, Hannah L. Tumbrink, Sebastian Klein, Anna Schmitt, Reinhard Büttner, Thorsten Persigehl, Kevan M. Shokat, F. Thomas Wunderlich, Alison M. Schram, Martin Peifer, Martin L. Sos, H. Christian Reinhardt, Roman K. Thomas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 821–830.
https://doi.org/10.1158/1535-7163.MCT-21-0820
Published: 04 May 2022
View articletitled, CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Open the PDF for CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization in another window
Includes: Supplementary data
Journal Articles

A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors

Free
Chester E. Chamberlain, Michael S. German, Katherine Yang, Jason Wang, Henry VanBrocklin, Melanie Regan, Kevan M. Shokat, Gregory S. Ducker, Grace E. Kim, Byron Hann, David B. Donner, Robert S. Warren, Alan P. Venook, Emily K. Bergsland, Danny Lee, Yucheng Wang, Eric K. Nakakura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (12): 2702–2709.
https://doi.org/10.1158/1535-7163.MCT-17-1204
Published: 03 December 2018
View articletitled, A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors
Open the PDF for A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors in another window
Includes: Supplementary data
Journal Articles

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib

Free
Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson, Simon McDade, James Campbell, Asha Kigozi, Rumana Rafiq, Helen Pemberton, Rachel Natrajan, Josephine Joel, Holly Astley, Claire Mahoney, Jonathan D. Moore, Chris Torrance, John D. Gordan, James T. Webber, Rebecca S. Levin, Kevan M. Shokat, Sourav Bandyopadhyay, Christopher J. Lord, Alan Ashworth
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1472–1484.
https://doi.org/10.1158/1535-7163.MCT-15-0554
Published: 05 July 2016
View articletitled, Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Open the PDF for Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib in another window
Includes: Supplementary data
Journal Articles

Abstract PR01: Inhibitory role of phosphatidylinositol-3,4-bisphosphate in triple-negative breast cancers

Free
Darien E. Reed, Kevan M. Shokat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7_Supplement): PR01.
https://doi.org/10.1158/1538-8514.PI3K14-PR01
Published: 06 July 2015
View articletitled, Abstract PR01: Inhibitory role of phosphatidylinositol-3,4-bisphosphate in triple-negative breast cancers
Journal Articles

Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma

Free
Nan Li, Dustin J. Maly, Yvan H. Chanthery, Daniel W. Sirkis, Jean L. Nakamura, Mitchel S. Berger, C. David James, Kevan M. Shokat, William A. Weiss, Anders I. Persson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (2): 419–428.
https://doi.org/10.1158/1535-7163.MCT-14-0526
Published: 09 February 2015
View articletitled, Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma
Open the PDF for Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract PR15: Primary resistance to MAPK inhibition in BRAF-mutant cancer is determined by kinetics of feedback release

Free
Martin L. Sos, John D. Gordan, Kevan M. Shokat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR15.
https://doi.org/10.1158/1535-7163.PMS-PR15
Published: 01 May 2014
View articletitled, Abstract PR15: Primary resistance to MAPK inhibition in BRAF-mutant cancer is determined by kinetics of feedback release
Journal Articles

Abstract PL04-03: Selective inhibition of K-Ras G12C through allosteric control of GTP affinity and effector interactions.

Free
Jonathan M. Ostrem, Ulf Peters, Martin L. Sos, James A. Wells, Kevan M. Shokat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): PL04-03.
https://doi.org/10.1158/1535-7163.TARG-13-PL04-03
Published: 01 November 2013
View articletitled, Abstract PL04-03: Selective inhibition of K-Ras G12C through allosteric control of GTP affinity and effector interactions.
Journal Articles

Abstract A180: Selective inhibition of K-Ras G12C through allosteric control of GTP affinity and effector interactions.

Free
Ulf Peters, Jonathan M. Ostrem, Martin L. Sos, James A. Wells, Kevan M. Shokat
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A180.
https://doi.org/10.1158/1535-7163.TARG-13-A180
Published: 01 November 2013
View articletitled, Abstract A180: Selective inhibition of K-Ras G12C through allosteric control of GTP affinity and effector interactions.
Journal Articles

Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma

Free
Jack S. Chen, Linda J. Zhou, Michal Entin-Meer, Xiaodong Yang, Mila Donker, Zachary A. Knight, William Weiss, Kevan M. Shokat, Daphne Haas-Kogan, David Stokoe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 841–850.
https://doi.org/10.1158/1535-7163.MCT-07-0393
Published: 15 April 2008
View articletitled, Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma
Open the PDF for Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma in another window
Journal Articles

Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage

Free
Christopher M. Sturgeon, Zachary A. Knight, Kevan M. Shokat, Michel Roberge
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (4): 885–892.
https://doi.org/10.1158/1535-7163.MCT-05-0358
Published: 28 April 2006
View articletitled, Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage
Open the PDF for Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage in another window